JP2024170466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024170466A5 JP2024170466A5 JP2024147372A JP2024147372A JP2024170466A5 JP 2024170466 A5 JP2024170466 A5 JP 2024170466A5 JP 2024147372 A JP2024147372 A JP 2024147372A JP 2024147372 A JP2024147372 A JP 2024147372A JP 2024170466 A5 JP2024170466 A5 JP 2024170466A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- use according
- inhibitor
- additional anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025154024A JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062957758P | 2020-01-06 | 2020-01-06 | |
| US62/957,758 | 2020-01-06 | ||
| US202062985152P | 2020-03-04 | 2020-03-04 | |
| US62/985,152 | 2020-03-04 | ||
| US202063198803P | 2020-11-13 | 2020-11-13 | |
| US63/198,803 | 2020-11-13 | ||
| JP2022535120A JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
| PCT/US2021/012329 WO2021142002A1 (en) | 2020-01-06 | 2021-01-06 | Anti-ccr8 antibodies and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535120A Division JP7606518B2 (ja) | 2020-01-06 | 2021-01-06 | 抗ｃｃｒ８抗体及びその使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025154024A Division JP2025178337A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
| JP2025154025A Division JP2025178338A (ja) | 2020-01-06 | 2025-09-17 | 抗ｃｃｒ８抗体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024170466A JP2024170466A (ja) | 2024-12-10 |
| JP2024170466A5 true JP2024170466A5 (enExample) | 2025-02-12 |
| JP7793001B2 JP7793001B2 (ja) | 2025-12-26 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL321341A (en) | Anti-CCR8 antibodies and their uses | |
| JPWO2021142002A5 (enExample) | ||
| JP7608164B2 (ja) | 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ | |
| Gan et al. | Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy | |
| CN108601828B (zh) | 包含抗folr1免疫缀合物的治疗组合 | |
| JP7137474B2 (ja) | ＮａＰｉ２ｂ標的化抗体－薬物コンジュゲート及びその使用方法 | |
| JP2018525354A5 (enExample) | ||
| TW201834697A (zh) | Her2標靶抗體－藥物結合物之組合療法 | |
| US12234293B2 (en) | Treatment for primary amyloidosis with anti-BCMA binding protein | |
| CN118078987A (zh) | 抗folr1免疫缀合物与抗pd-1抗体的组合 | |
| CN112218662A (zh) | 抗cd37免疫缀合物给药方案 | |
| JP2019023227A (ja) | 神経障害及び疼痛のｅｇｆｒ標的治療 | |
| TW202116810A (zh) | 用於治療癌症之人化抗ｌｉｖ１抗體 | |
| EP3691682A1 (en) | Combination treatment for cancer | |
| IL322208A (en) | Methods and preparations for combined therapy | |
| AU2022331610A1 (en) | Interleukin-12 variants and methods of use | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2024170466A5 (enExample) | ||
| TW202306588A (zh) | 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途 | |
| TW202508637A (zh) | 修飾的抗體、其抗體片段和抗體藥物偶聯物 | |
| KR20250069817A (ko) | Pd-1 또는 pd-l1 억제제 및 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트를 사용한 암 치료 | |
| KR102544135B1 (ko) | c-Kit을 표적으로 하는 면역접합체 | |
| Junttila et al. | 515 POSTER Trastuzumab-mertansine (T-DM1) retains all the mechanisms of action (MOA) of trastuzumab and is extremely effective in combination with docetaxel | |
| WO2025238587A1 (en) | Combination of anti-b7-h3 antibody-drug conjugate and androgen receptor signaling inhibitor | |
| TW202506722A (zh) | 使用pd-1或pd-l1抑制劑及靶向密連蛋白(claudin) 18.2之抗體藥物結合物之癌症治療 |